According to the International Diabetes Federation (IDF) Atlas, diabetes prevalence (9.2%) and number of people with diabetes (61 million) in EUR Region will increase 13 % by 2045. EUR Region has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.
The EUR Region has also the second highest average cost per person with diabetes (USD 3,086). In 2021, 189.3 billion USD was spent on diabetes, representing 19.6% of the total spent worldwide.
These figures clearly reflect the importance of diabetes treatment in European health systems and the need to ensure sustainability in patient care.
In the sense, generic drugs play a fundamental role in the treatment of patients. According to Medicines for Europe, almost 20 million people across Europe are now being treated for diabetes with generics (around 30%). However, the expected increase in the prevalence of this disease announced by the IDF may generate a significant problem for public health systems, which will have to face a considerable rise in the number of patients.